Prior SARS‐CoV‐2 infection balances immune responses triggered by four EMA‐approved COVID‐19 vaccines: An observational study

• Published in: Clinical and translational medicine Vol. 12; no. 5; pp. e869 - n/a
• Main Authors: Lozano‐Rodríguez, Roberto, Terrón‐Arcos, Verónica, Montalbán‐Hernández, Karla, Casalvilla‐Dueñas, José Carlos, Bergón‐Gutierrez, Marta, Pascual‐Iglesias, Alejandro, Quiroga, Jaime Valentín, Aguirre, Luis A., Pérez de Diego, Rebeca, Vela‐Olmo, Carmen, López‐Morejón, Lissette, Martín‐Quirós, Alejandro, del Balzo‐Castillo, Álvaro, Peinado‐Quesada, María A., García‐Garrido, Miguel A., Gómez‐Lage, Laura, Herrero‐Benito, Carmen, Llorente‐Fernández, Irene, Martín‐Miguel, Gema, Torrejón, Margarita, Cubillos‐Zapata, Carolina, del Fresno, Carlos, Avendaño‐Ortiz, José, López‐Collazo, Eduardo
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2022; John Wiley and Sons Inc; Wiley
• Subjects: Antibodies; Coronaviruses; COVID-19 vaccines; Disease transmission; Immunization; Infections; Letter to the Editor; Severe acute respiratory syndrome coronavirus 2; Spain

Other authors have reported that in natural infection anti-Spike RBD IgA antibodies showed to be the major responsible of the neutralizing ability in early stages.2 Regarding the cellular response, CD4+ but not CD8+ T-cell activities against SARS-CoV-2 spike peptide pool (Supporting information Figu...